Their research in CKD rats revealed that butyrate treatment strengthens the intestinal barrier while also stimulating the secretion of glucagon-like peptide-1 (GLP-1) and increasing the phosphorylation of AMPK in the colon. Here, GCG is linked to chronic kidney disease.